Perrin F. Disner (SBN 257586) LAW OFFICES OF PERRIN F. DISNER 4630 Sepulveda Boulevard, Suite 105 Sherman Oaks, California 91403 Tel: (310) 742-7944 3 Fax: (888) 544-5154 Suparior dount of palifornia County of Los Angeles pdisner@disnerlaw.com 4 Attorneys for Plaintiffs OCT 23 2017 5 Sherri R. Carter, Executive Officer/Clerk 6 gostel-7 8 SUPERIOR COURT OF THE STATE OF CALIFORNIA IN AND FOR THE COUNTY OF LOS ANGELES 9 10 BC 680843 EMILY ELSON, STACY HAAVISTO, CASE NO. LORETTA OAKES, MICHELLE 12 LANUM, JULIA LEFEBVRE, SUE **CLASS ACTION COMPLAINT FOR:** GRLICKY, TILLY DORENKAMP, 1. FALSE ADVERTISING (CAL. CIV. 13 DINA SALAS, ARLENE RODRIGUEZ, **CODE § 1770)** JERRY GAINES, and all others 2. STRICT PRODUCT LIABILITY similarly situated, DESIGN DEFECT 15 3. STRICT PRODUCT LIABILITY -Plaintiffs, FAILURE TO WARN 16 4. NEGLIGENCE VS. 5. NEGLIGENCE PER SE 17 6. GROSS NEGLIGENCE ASHLEY BLACK, an individual, 7. RECKLESS MISCONDUCT 18 ASHLEY DIANA BLACK 8. BREACH OF EXPRESS WARRANTY INTERNATIONAL HOLDINGS, LLC, 19 9. BREACH OF IMPLIED WARRANTY: a Delaware Corporation, ADB FITNESS FOR PARTICULAR PURPOSE INTERESTS LLC, a Texas Corporation. 20 10. BREACH OF IMPLIED WARRANTY: and DOES 1-100, MERCHANTIBILITY 21 Defendants. 11. DECEIT/INTENTIONAL FRAUD 22 12. DEFAMATION 13. INTENTIONAL INFLICTION OF 23 EMOTIONAL DISTRESS 14. UNFAIR BUSINESS PRACTICES (CAL. 24 BUS. & PROF. CODE §§ 17200 et seq.) 15. FALSE ADVERTISING (CAL. BUS. & --25 PROF. CODE §§ 17500 et seg.) 26 JURY TRIAL DEMANDED 27 28

9

11

12 13

14 15

16

17 18

19

21

2223

24

25

26 27

28

Plaintiffs Emily Elson, Stacy Haavisto, Loretta Oakes, Michelle Lanum, Julia Lefebvre, Sue Grlicky, Tilly Dorenkamp, Dina Salas, Arlene Rodriguez, and Jerry Gaines ("Plaintiffs") on their own behalf and on behalf of all others similarly situated, bring this action for injunctive relief and for damages under the laws of the State of California.

I. <u>INTRODUCTION</u>

- 1. Defendants Ashley Black ("Black"), Ashley Diana Black International Holdings, LLC, Adb Interests, LLC, and DOES 1-100 (collectively "Defendants") manufacture, test, market, endorse, distribute and/or sell a putative medical device called "FasciaBlaster" which not only (a) did and does fail to deliver the aesthetic results stridently guaranteed by Defendants' false and deceptive advertising, but which moreover (b) did and does cause a wide array of physical injuries exemplified by the experiences of the Plaintiffs, running the gamut from simply worsening the aesthetic conditions which the device is supposed to improve, to far more severe harms such as extreme hormonal instability, stroke, and others described herein. Furthermore, when some of the Plaintiffs justifiably discussed their dangerous and scary FasciaBlaster experiences within Internet social media forums, hoping to find answers and to help minimize the risks to others, Defendants responded with (c) censorship and a vicious, vindictive campaign of orchestrated defamation, harassment, cyber-bullying, intentional infliction of emotional distress, and malicious prosecution.
- 2. Currently selling for \$89, the FasciaBlaster is ostensibly a massage 'stick' with handles on both ends and a set of hard plastic claws protruding from

Various versions of the device, differing mainly in size, are advertised for use on different parts of the body, e.g. "FaceBlaster," however all versions have the central 'claw' features in common, and all are marketed as operating on roughly the (footnote continued)

the middle. Its damage is done when a user follows Defendants' marketing and instructional materials' direction: first, to heat up the target area of the body e.g. in a sauna, then to strenuously, painfully rake² the claws over one's heated skin. Defendants direct users to 'blast' at a pain level of "7 out of 10" in pursuit of a laundry list of exciting results promised by Defendants, including cellulite reduction, improved skin tone and muscle definition, and other health and beauty benefits. Some FasciaBlaster marketing assertions, e.g. that 'blasting' relieves symptoms of Multiple Sclerosis and Parkinson's disease, or that it is "completely safe for children!" are particularly galling. And of course, Defendants assert that said benefits are all the more likely when one also purchases from their line of approved FasciaBlaster accessories, including expensive skin creams and oils for use with the device.

- 3. In addition to the foregoing false advertising, Defendants did and do make deceptive public representations e.g. regarding U.S. Food and Drug Administration ("FDA") approval of the FasciaBlaster, regarding the scientific testing their devices have undergone, and regarding the academic and medical credentials of multiple agents and employees whom Defendants did and do feature prominently in FasciaBlaster advertising and instructional materials.
- 4. On information and belief, Defendants have long known that FasciaBlaster can be dangerous, but instead of issuing a recall or ceasing to sell the devices, they have persevered in commerce largely indifferent to the harms the

same principle via the same general type of usage, i.e. aggressive self-massage over targeted connective tissue. As such, to avoid confusion this Complaint refers to all versions of the device under the umbrella term "FasciaBlaster" except where a distinction between versions may be pertinent for e.g. narrative purposes.

² 'Blasting' is the vernacular term Defendants use in their marketing and instructional materials, and which Plaintiffs adopt herein, as shorthand for the directed use of the FasciaBlaster.

1

4 5

6 7

9

11

12

10

13 14

15

16 17

18 19

20

22

23

24

25 26

26 27 28 device did and will continue to cause. Instead of real accountability, Defendants occasionally make mere minor adjustments to their marketing or directions for use—presenting an air of authority while offering meaningless bromides such as "blast for 5 minutes instead of 10" and "use less heat first"—along with the aforementioned deliberate and callous campaign of intimidation against their dissatisfied and/or injured customers.

5. The named Plaintiffs, along with all others similarly situated, were taken in and victimized by Defendants' deceptive business practices. Each named Plaintiff, and others similarly situated, has suffered as a result of Defendants' negligence, gross negligence, recklessness, and fraud in the manufacture, testing, marketing, endorsement, distribution, and sale of a dangerous device with directions for dangerous use coming from Defendants' medically unqualified and incompetent spokespeople. For product liability purposes, the proposed Plaintiff class may be divided into subclasses based on the array of physical maladies attributable to FasciaBlaster which the various named Plaintiffs have suffered, as detailed herein. For example, Plaintiffs may ultimately seek to certify e.g. Subclass A consisting of individuals who have suffered endocrine problems; Subclass B consisting of individuals who have suffered cardiovascular problems; Subclass C consisting of individuals who have suffered digestive problems; Subclass D consisting of individuals who have suffered neurological problems; Subclass E consisting of individuals who have suffered psychological problems; Subclass F consisting of individuals who have suffered defamation, harassment, or cyber-bullying; and Subclass G consisting of individuals who have suffered from aesthetic harms, e.g. the worsening of cellulite or wrinkles after use of a FasciaBlaster purchased and/or used based on Defendants' aggressive representations that it would have precisely the opposite effect. This Court is asked to expeditiously and actively enforce the many laws at issue, in order both to provide redress for the physical injuries already

suffered and to prevent countless such injuries from continuing to occur in the future.

II. JURISDICTION

- 3. Plaintiffs Elson and Haavisto are residents of Los Angeles County.
- 4. The Defendants include an individual—Ashley Black—who on information and belief resides in Los Angeles County, whom the Plaintiffs hereby sue in her personal capacity for acts and omissions by her (for both monetary and nonmonetary³ purposes) and because two other Defendants, corporations of which she is President, sole or controlling shareholder, or otherwise principal, qualify as her alter egos on information and belief, justifying the Court in piercing corporate veils.
- 5. Further, this Court has personal jurisdiction over the Defendants hereto because any Defendants which are not California residents are nevertheless subject to California's long-arm statute by virtue of *inter alia* the fact that they avail themselves of the protection of California law in their commercial dealings in California's marketplace, which dealings are ample and the subject of this lawsuit. Specifically, the Defendants advertise and promote use of their products to potential customers in California via e.g. the Internet, television, and in print, and sell their products in California via e.g. online purchase or mail-order. The foregoing constitutes well more than the minimum commercial contacts with California necessary to provide this Court with personal jurisdiction over Defendants pursuant to *Fireman's Fund Ins. Co v. National Bank of Cooperatives*, 103 F.3d 888, 893 (9th Cir. 1996) and *International Shoe Co. v. Washington*, 326 U.S. 310, 316 (1945).

³ Defendant Black relishes her status as a self-designated celebrity health "guru," providing her with personal, nonmonetary egocentric benefits subject to proof, above and beyond the personal and corporate financial rewards of her actions.

ِ

III. PARTIES

DEFENDANTS

- 6. On information and belief, Defendant Ashley Black is an individual living in Manhattan Beach, California. On information and belief, Black is the President, CEO, principal, majority shareholder, or only shareholder of both Ashley Diana Black International Holdings, LLC and Adb Interests, LLC. On information and belief, there are grounds on which this Court may find that said corporations are Black's alter egos, and pierce one or both corporate veils as appropriate to hold her personally liable for their acts and omissions.
- 7. Defendant Ashley Diana Black International Holdings, LLC ("ADBIH") is a Delaware limited liability company headquartered, on information and belief, in Pearland, Texas. On information and belief, ADBIH is a close corporation controlled by, and qualifying as an alter ego of, Defendant Ashley Black. On information and belief, ADBIH was incorporated to own/manage intellectual property, i.e. trademarks and patents pertaining to the device(s) known as FasciaBlaster and assorted accessories for use therewith. Other than the foregoing corporate functions, the full and precise nature of ADBIH's relationship with the other Defendants is unknown at this time, and Plaintiffs will seek leave of Court to amend this description if necessary after discovery.
- 8. Defendant Adb Interests, LLC ("ADBI") is a Texas limited liability company headquartered, on information and belief, in Pearland, Texas. On information and belief, ADBI is a close corporation controlled by, and qualifying as an alter ego of, Defendant Ashley Black. On information and belief, ADBI produces, promotes, and sells FasciaBlaster devices and the assorted accessories sold for use therewith; on information and belief, ADBI does business as ADB Innovations LLC for purposes of distributing the skin creams and oils. Other than the foregoing, the full and precise nature of ADBI's relationship with the other

Defendants is unknown at this time, and Plaintiffs will seek leave of Court to amend this description if necessary after discovery.

9. At this time, the true names and capacities—individual, corporate, associate or otherwise—of Defendants DOES 1 through 100, inclusive, are unknown to Plaintiffs, who thus sue said DOES by such fictitious designation until such time as Plaintiffs are adequately informed about them, including *inter alia* their respective degrees of and reasons for personal liability, to seek leave of the Court to amend this Complaint to include their true names. On information and belief, each of the DOE Defendants bears some degree of liability to Plaintiffs, and others similarly situated, for the unlawful acts and omissions described herein.

PLAINTIFFS

10. Each of the Plaintiffs named herein purchased and/or used FasciaBlaster, and between them they suffered a wide variety of severe harms therefrom as described herein.

A. Emily Elson

- 11. Emily Elson ("Elson"), age 40, is an individual who resides in Los Angeles, California. Elson first purchased a FasciaBlaster device in or around March of 2017 because she saw advertising—on social media website Facebook—which touted the device's ability to reduce cellulite. Elson then 'blasted' as directed by Defendants' marketing and instructional materials, i.e. raked the device over her heated skin, all over her body except for her head, neck, and face, approximately once per week for a mere four or five weeks, before stopping when a host of physical ailments began to arise.
- 12. Elson has been and is planning to undergo artificial insemination. As of early 2017, in light of her teaching schedule she planned to undergo the procedure in June or July of 2017 (in order that her maternity leave at the end of the Spring 2018 semester would lead into her Summer break, allowing her to devote maximum time

to infant care and bonding) without unduly delaying the attempt beyond the already fraught, well-known 40-years' benchmark. According to ample research (subject to proof), after 40 years of age, women find e.g. fertilization more difficult to achieve, egg quality degraded, egg numbers reduced, and that the risk of birth defects increases significantly. In order to maximize her odds of conceiving a healthy baby, Elson diligently underwent regular testing to monitor her reproductive hormone levels, including *inter alia* Follicle-Stimulating Hormone ("FSH"), and Luteinizing Hormone ("LH"), Progesterone, and Estrogen. Blood tests taken shortly before she began 'blasting' showed all of the foregoing hormones within better-than-average ranges. Prior to the events described herein, Elson had last undergone a test for Anti-Mullerian Hormone ("AMH" which indicates 'ovarian age,' i.e. overall fitness for fertilization) at age 38, at which time her AMH levels were optimal.

- 13. After 'blasting' for only a short period in or around March of 2017, Elson became very ill. She is a carrier of the Epstein-Barr virus, and had successfully managed that condition with *inter alia* natural supplements, keeping 'flare ups' at bay for approximately two years before she began 'blasting.' Immediately after 'blasting,' however, she experienced an abrupt, aggressive and painful flare up of Epstein-Barr virus symptoms, persisting to the date hereof. On information and belief, 'blasting' released and reactivated dormant virus cells which had previously been trapped benignly within e.g. subcutaneous fat cells, a conclusion which Elson and multiple health practitioners later reached after *inter alia* learning about other FasciaBlaster users' having had the same experience with cases of 'reactivated' Epstein-Barr, Shingles, Lyme disease, etc.
- 14. In addition to the foregoing, promptly after 'blasting' Elson began to experience intense menstrual and other unusual hormonal side-effects, different in nature and severity than any variations she had previously experienced. Her next round of reproductive hormone laboratory testing, undertaken within 6 weeks after

15. Beyond the foregoing illnesses, pain, hormonal swings, and emotional distress Elson suffered as a result of her 'blasting,' the appearance of cellulite which she had sought to reduce instead became—and remains—significantly more conspicuous.

B. Stacy Haavisto

1

5

6

7

8

9

10

11

12

13

15

17

18

20

21

22

23

24

26 27 28 California. She uses Facebook daily, and was subject to aggressive targeted FasciaBlaster advertising thereon. Desiring to reduce cellulite and lose weight, she gave in to the targeted ads and purchased her first FasciaBlaster in or around April of 2016. She promptly began 'blasting' approximately five times per week for approximately three months, then more sporadically until ceasing to 'blast' in March of April of 2017. She ultimately spent roughly \$500 on various FasciaBlaster devices and accessories.

⁴ Elson's low AMH level was especially upsetting because, ordinarily, AMH levels only ever decrease over time; significant AMH increases are extremely rare. Elson was thus very fortunate when, after 10+ weeks of depression and anxiety following her "compromised fertility" result, her next AMH test—between four and five months after she had ceased 'blasting' once and for all—showed surprising improvement. Although AMH decrease between ages 38 and 40 is normal, Elson attributes the circumstance to the FasciaBlaster on information and belief because the significant AMH *increase*, months later, is extraordinarily unusual.

- 18. The foregoing finally made Haavisto cease 'blasting' in July 2016, and forced her to spend the next three months with drastic dietary and other lifestyle changes through October of 2016. Her aggressive new health regimen caused her to lose 36 pounds, and her skin hung loose off of her body, so she began 'blasting' again in an attempt to firm herself back up. Without any other change to her lifestyle besides the renewed 'blasting' routine, Haavisto promptly regained eight pounds.
- 19. In January of 2017, Haavisto was suffering symptoms of severe hormonal fluctuation, including hair loss and loss of collagen in her face. Based on Defendants' assertions that FasciaBlaster simply has no hormonal impact, and in light of conversations in a Facebook discussion group (which Defendants carefully monitor and control) attributing Haavisto's symptoms to 'breast implant issues', she needlessly had her breast implants surgically removed on January 31. Nevertheless, in March of 2017, Haavisto's hormonal symptoms were explained by a formal diagnosis of 'Adrenal Fatigue, which her physician found totally puzzling due to Haavisto's age and healthy lifestyle⁵.
- 20. Moreover, by March her cellulite had returned tenfold to her thighs. 'Blasting' also left unsightly 'rake marks' on her thighs and calves, and dangerous

⁵ Haavisto's doctor expressly confessed to being confused by the patient's condition, before ultimately attributing it to "toxic overload." Here, FasciaBlaster's high content of Bisphenol A ("BPA") is worthy of note. <u>See</u> Para. 86, *infra*.

 inflammation; to gauge the latter, Haavisto underwent a C-Reactive Protein ("CRP") blood test. CRP level of 1 is normal. Haavisto's blood test showed her CRP level at 8, very dangerously high.

- 21. As of October 2017, the sustained ramifications of Haavisto's 'blasting' include Oxidative Stress, a severely dangerous condition affecting the body's ability to remove toxins and repair cell damage which studies have connected to an array of terrible ailments, including *inter alia* Parkinson's Disease, Alzheimer's Disease, heart failure, chronic fatigue syndrome and depression. Haavisto also now suffers Metabolic Syndrome attributable to 'blasting,' increasing her risk of heart disease, stroke, and diabetes. She also continues to chronically suffer brain fog, insomnia, stiff neck, and headaches.
- 22. Haavisto came forward and wrote about the foregoing dangerous and scary experiences in a public FasciaBlaster discussion group on Facebook. Defendants promptly removed her comments and kicked her out of the group, and thereafter retaliated against her by harassing, intimidating, cyber-bullying and defaming her, and on information and belief, by soliciting third parties to harass, intimidate, cyber-bully and defame her, as well. The latter conduct included *inter alia* overtly encouraging Defendants' more loyal Facebook followers to attack Haavisto e.g. by leaving false negative reviews of her own businesses' Facebook pages, and by targeting her with groundless accusations to the authorities, as exemplified by a public Facebook post on September 7, 2017, to wit:

Everyone. Let's report Dari, Julie D L, Veronica Verona, Stacy Havisto [sic], Danielle Reins, Tammy Wike, and everyone else in their hate group to the FTC, FDA, FBI, the DEA, and their local Police Stations.

Let's look up their businesses and leave 1 star reviews.

Let's make sure everyone knows the truth about how hateful they are and all of the shadiness.

You don't have to have been personally injured by them. If you know anyone who has spent anytime [sic] reading their lies then you have been injured

7 8

10

9

12

11

13 14

15

16 17

18

19 20

22

23

21

///

2425

26 27 (permanently). You can't get that part of your life back.

I'll make it easy for everyone. I'll create a copy/paste list of things they have done:

- -Harrassment [sic]
- -Cyber Bullying
- -Extortion
- -Tortuous [sic] Interference
- -Defamation
- -Product Libel
- -Hate Crimes
- -Defrauding the Government (abuse of gov systems)

You can do it anonymously. Just crop out your face. Don't worry about negative repercussions. There is nothing they can do. We need to do this in order to get the truth out and take them down.

Come on everyone, let's do this!!!!!!

I will send separate e-mails to everyone with guidance from "you know who"

The foregoing was posted publicly by a putative Facebook user named Sarah Minow, although Ms. Minow's personal Facebook page appears to be fake⁶. On information and belief, Defendant Black herself created this 'shill' Facebook profile in order to post the foregoing 'call to arms,' and the allusion therein to "you know who" refers to Defendant Black.

23. All told, on information and belief Haavisto's expenses in connection with using FasciaBlaster and dealing with its aftermath exceeded \$10,000.

⁶ Ms. Minow's Facebook page displays no photos, no friends, no posts, and no information of any kind, save for two telling details: (i) under the heading "Groups" Ms. Minow discloses only that she is a member of "FasciaBlasters Official Open Forum", and (ii) under the heading "Contact Information" the sole entry—"http://facebook.com/sarah.minnows"—wherein Ms. Minow mysteriously seems to have misspelled her own name.

3 N 4 S 5 N 6 F 7 m 8 't

1

2

- 10 11
- 13 14

12

- 15 16
- 18

17

- 20 21
- 22 23
- 2425
- 26 27 28

- 24. Loretta Oakes ("Oakes") is an individual who resides in Las Vegas, Nevada. After conducting ample research about cellulite reduction, in or around September of 2016 Oakes purchased the standard FasciaBlaster device. In or around November of 2016, she purchased another version, the "Mini 2." In or around February 2017, she purchased yet another version, the "Faceblaster," along with multiple creams and oils marketed by Defendant for use with the devices. Oakes 'blasted' as directed in Defendants' marketing and instructional materials, exacerbating a peripheral neuropathy condition such that she then suffered near-constant tingling in her feet and sometimes too much pain to walk, including as recently as within the last month. She was bedridden from November 2016 through January 2017, other than for doctor appointments.
- 25. Oakes's 'blasting' caused severe bruising which has lingered as hemosiderin staining on her legs for over six months since she ceased 'blasting' in approximately March of 2017. Further, by disrupting the tissue connecting skin to muscle, 'blasting' has turned the skin on her legs and stomach crêpey, i.e. loose and wrinkled worse than her elderly mother's skin.
- 26. On information and belief, other harms attributable to 'blasting' which Oakes has suffered include depression (with suicidal ideation), anxiety, nausea, panic attacks, and lightheadedness, at least one incident of which caused her to lose consciousness and collapse. Even after she stopped 'blasting,' Oakes's depression and anxiety have persisted due to personal attacks and falsehoods leveled against her on social media by Defendant Ashley Black, and by others defaming and harassing Oakes at Black's behest, on information and belief.
- 27. Oakes has spent several thousands of dollars on doctor visits, pain management, and a variety of expensive skin treatments in attempts to repair the damage wrought by FasciaBlaster.

C. Michelle Lanum

1-2

- 28. Michelle Lanum ("Lanum") is an individual who resides in Tampa, Florida. Lanum is pursuing her Ph.D. in Psychology from Kaiser University, with focus on the mind-body connection. When an acquaintance told her about FasciaBlaster, Lanum looked into it and decided it would be a perfect subject for study in connection with her degree, and she also saw an opportunity to reduce her own scarring from a caesarian section several years earlier. Lanum purchased multiple FasciaBlaster devices in November of 2016 and began 'blasting' as directed.
- 29. When it came to her attention that Defendants were conducting a putative "clinical trial" for the device at the Applied Science & Performance Institute ("ASPI") right in her own neighborhood, Lanum jumped at the opportunity to be able to observe the study for academic purposes, and to participate for her own aesthetic reasons. She participated in ASPI's putative clinical trial of the FasciaBlaster from December 10, 2016 through March 10, 2017.
- 30. Commencing with Lanum's participation in the putative clinical trial, she promptly became severely ill due to 'blasting,' on information and belief. Her symptoms included nausea, vomiting, migraines, neck and shoulder pain, dizziness, and severe gastrointestinal distress alternating between prolonged and painful constipation to violent diarrhea. Lanum quickly lost 16 pounds, then three more pounds. She regularly communicated these experiences to putative clinical trial "researcher" Kathleen Stross, who repeatedly asserted that any notions of a connection between Lanum's symptoms and the 'blasting' were refuted by Lanum's regular blood testing results and other data the putative study was purportedly gathering. On information and belief, the foregoing was an outright falsehood, and contrary to Defendants' repeated promises to return study participants' medical test results to them, Defendants and the putative researchers have still not done so,

- 31. Continued 'blasting' brought out severe varicose and spider veins on Lanum's legs which had not previously been apparent, and caused an increase in the appearance of cellulite. When Lanum and multiple other participants in the putative clinical trial mentioned the appearance of new varicose veins, the putative researchers explicitly denied that there was any connection to 'blasting,' then later asserted that the varicose veins might get worse but would ultimately disappear.
- 32. More than six months after terminating her use of the FasciaBlaster, Lanum's legs still exhibit varicose veins, rake marks, and crêpey skin, none of which had been present before 'blasting.' Lanum continues to suffer semi-regular bouts of dizziness, nausea, tinnitus, sciatica, knee problems, and nerve pain and tingling radiating down through her shoulders and arms, all of which on information and belief are results of nerve damage attributable to her 'blasting' over six months ago. Lanum has been prescribed and is currently undergoing a course of physical therapy to address her persistent nerve pain, which she and her physical therapist hope will also curtail her frightening dizziness and tingling in her arms.
- 33. In Lanum's judgment based on her personal academic background and experience, she found the putative researchers' behaviors to be highly erratic, their methods unprofessional, and the putative clinical trial to be unscientific and improper. Further, Lanum learned that Bart Jameson—one of the putative researchers whom Defendants' video(s) had referred to as "Doctor Bart"—is, in fact, not a doctor. When Lanum would ask procedural questions of the putative researchers, e.g. for the benefit of her own research, their replies revealed shocking unfamiliarity with the scientific process, generally. In one notable instance, Lanum found that she had to explain to Jameson what a "hypothesis" is, and that it ordinarily comes before an experiment, not after.

Doc# 1 Page# 16 - Doc ID = 1714516271 - Doc Type = OTHER

2

3

4

5

11

12

13

15

17

21

23

24

25

<u>2</u>6 چ

28 5 35. Defendants' putative clinical trial's physical impact on Lanum was so debilitating that it forced her to drop out of a required graduate school class—Cross-Cultural Methods of Tests and Measurements—which then cost her \$3,600 to retake the following semester. Adding insult to injury, plus more injury, due to the ASPI study's countless procedural and administrative flaws, Lanum was subsequently unable to use her experience therein for the benefit of her doctoral dissertation, as had been her aim all along. This wasted time and effort will now require her to extend the time for her dissertation research, at the cost of an additional \$6,600 in tuition for the extra semester. Finally, treatment measures to repair the damage wrought by Lanum's FasciaBlaster experience have cost over \$600 to date, on information and belief, and she expects that she may ultimately require costly plastic surgery if her currently ongoing treatments ultimately prove

⁷ 'Re-experience' is the clinical terminology associated with the phenomenon whereby e.g. Post Traumatic Stress Disorder ("PTSD") patients feel their previous trauma all over again, as though it were happening in the present.

ineffective.

D. Julia Lefebyre

- 36. Julia Lefebvre ("Lefebvre") is an individual who resides in Hiram, Maine. Lefebvre is an independent contractor performing background checks and employee and renter screenings. Lefebvre and her husband booked a cruise for November 2016 in order to renew their marriage vows, in preparation for which Lefebvre researched "cellulite reduction" on the Internet in order to look her best in bathing suit or short skirt for her romantic vacation. Her research caused Facebook's advertising algorithm to begin targeting her with FasciaBlaster ads, which then led her to the FasciaBlaster website, Defendants' promotional videos, and public Internet forums populated by 90,000+ putative satisfied customers, wherein Lefebvre noted a lack of any negative feedback whatsoever. She purchased FasciaBlaster in September 2016 and promptly began 'blasting' five times per week.
- 37. Though Lefebvre had purchased FasciaBlaster only to reduce cellulite on her thighs, Defendants' marketing promises led her to also 'blast' her face, neck, arms, stomach, back and buttocks regularly. Before long her thighs, stomach, back and arms began to show severe bruising, but she carried on 'blasting' based on Defendants' admonition that results would be "worse before better!" Lefebvre followed Defendants' instructions and encouragement to the effect that her 'blasting' build up to a pain level of "seven out of 10," that she "blast down to the bone," and that "violent blasting does a body good." Lefebvre ceased blasting in the last week of October 2016, in order that her accumulated bruises would have time to fade away before her cruise, but the bruises simply changed color and remained as ugly hemosiderin stains all over her 'blast' areas. To make matters worse, the appearance of cellulite on her thighs had significantly worsened. The discoloration and cellulite made her too self-conscious to wear shorts, bikini, or a short skirt, thus ruining what was supposed to be a romantic vacation.

2

3

6

7

8

11

12

13

15

17

18

20

21

22

23

24

25

39. Lefebvre continued to suffer debilitating panic attacks multiple times per week until shortly after she ceased 'blasting' in May 2017. Her last such attack was in June, but she felt compelled to refrain from driving her car between January and August of 2017, other than a handful of short trips alone to the market, for fear of an accident. These attacks understandably affected her ability to work and engage with her family and others, constituting a severe impact on her quality of life

⁸ On information and belief, this and subsequent similar episodes were not panic attacks, but Vasovagal Syncope, however the Complaint refers to them as panic attacks for clarity's sake to convey the abruptly incapacitating pain, anxiety, weakness, and loss of physical control.

- 40. Beginning in January 2017, Lefebvre noticed newly rapid aging in her face, including dramatic deepening of the so-called 'marionette lines.' Since then she has spent over \$4,000 on collagen treatments and supplements, laser therapy, microcurrent, microneedling, and other reparative measures to try to get her face back to its pre-'blasted' state. Furthermore, over three months after she ceased 'blasting,' Lefebvre's legs still have hemosiderin stains, unsightly rake marks, and worse cellulite than they exhibited a year ago.
- 41. Lefebvre has been subject to defamation, harassment, intimidation and cyber-bullying after she honestly relayed her experiences in e.g. the "Master Blaster" group on Facebook, including *inter alia* being mentioned in a Facebook group post on September 7, 2017 which explicitly sought to incite group members to *inter alia* attack Lefebvre's business with false negative online reviews. On information and belief, the putative Facebook user "Sarah Minow" who posted said incitement was in fact a fake 'shill' profile created and wielded by Defendant Black, herself, or at her behest. Likewise, putative Facebook user "Georgia Peach" falsely asserted that Lefebvre has committed fraud. On information and belief, "Georgia Peach" is also a shill profile created and wielded by Defendant Black.

E. Sue Grlicky

42. Sue Grlicky ("Grlicky") is an individual who resides in Brooklyn, Ohio. A 52 year-old office manager for a chemical company, Grlicky was in good health overall, but in the Spring of 2017she was suffering from lower back pain in her psoas muscle. She undertook research on the subject via Google, which on information and belief prompted Facebook to target her with an ad for FasciaBlaster. Grlicky then assiduously researched FasciaBlaster over the course of four weeks—she joined the "Ashley Black Guru" Facebook discussion group, reviewed over a hundred product reviews therein, watched numerous promotional

THE PROPERTY

and instructional videos, and purchased and read Defendant Black's book, <u>The Cellulite Myth: It's Not Fat, It's Fascia</u>, cover to cover—before purchasing the device and accessories in April of 2017. She commenced using it immediately, targeting her lower back, shoulders, neck, scalp, abdomen, buttocks, and legs (inner, outer, front, and back), for approximately one minute per target area, approximately five times per week after a hot bath.

- 43. Within her first week of 'blasting' Grlicky began to experience severe nausea, headaches, body aches, fatigue, and depression. She wrote to Black about her symptoms via Facebook, to which the latter responded that "detox can really be rough ... [it's] no fun but it's a necessary, TEMPORARY evil that is needed to release all the gunk that's keeping your body from functioning at 100%." Grlicky then took a break from 'blasting' for 2-3 days, then resumed 'blasting' as before, but more gently and for shorter duration, and her symptoms improved slightly in severity by the end of her second week, but did not go away.
- 44. During her third week of 'blasting,' Grlicky stumbled upon another Facebook discussion group, this one dedicated to FasciaBlaster's adverse effects, which caused her to draw the connection that her persistent illness was more than the mere beneficial 'detoxification' that Black had asserted it was, so Grlicky then ceased 'blasting.' Shortly thereafter, she experienced the abrupt onset of a stabbing, throbbing, burning neck and shoulder pain. This new symptom was severe, constant, and scary. Over the following few weeks Grlicky sought treatment from a chiropractor and four different massage therapists—one of whom told her that her neck and shoulder area was "highly inflamed"—until one day a tingling began to radiate down her right arm. Her chiropractor diagnosed her with a pinched nerve, and attempted a special chiropractic adjustment for that diagnosis, but it accomplished nothing. Desperate and afraid, Grlicky went to the Cleveland Clinic in early July, where she was referred to a neurologist who confirmed the pinched nerve

6 7

8

11 12

13 14

15

16

17 18 19

20 21

22 23

24

25 26

28

diagnosis. Grlicky underwent MRIs and x-rays, and the neurologist prescribed neuropathic medication Gabapentin and pain medication Tramadol. This course of treatment improved Grlicky's pain but did not fix it, and treatment efforts are ongoing.

- While at work on July 17, Grlicky felt a sudden mild pain in her hip, 45. which within 15 minutes became excruciating, whereupon she could not walk or stand. A call to 911 brought an ambulance to take Grlicky to the Cleveland Clinic Emergency Room, where she was subjected to CT scans, more x-rays, blood tests, etc. ER personnel asked her "were you in some kind of accident?" "No," she replied, "why?" She was then told that a burst blood vessel had caused a massive hematoma and internal bleeding in her pelvic region (left side). After trying and failing to find any exterior bruising in the area, the ER doctor told Grlicky that "this is highly unusual, not something we see often [other than after e.g. a violent collision]." Grlicky was admitted to the hospital for an overnight stay in order for doctors to stop her internal bleeding.
- 46. Since the foregoing hospital stay, Grlicky has had appointments with her primary doctor, a hematologist, physical and massage therapists, and a holistic practitioner. Nonetheless, Grlicky still experiences occasional pain on the left side of her pelvis, causing her to suffer extreme anxiety to ever be alone, lest her blood vessel burst again, or worse. Her primary doctor concluded that this entire episode was attributable to Grlicky's 'blasting,' and explicitly stated "you easily could have died from internal bleeding. You should sue those people [Defendants]." Grlicky also now suffers great anxiety about the possibility of losing her job, having had to take off work to some degree roughly every week since her pinched nerve for medical or therapeutic appointments, or on occasions when her pain is unbearable.
- All of Grlicky's medical treatment described herein—including trips to the Cleveland Clinic, ER, ambulance, chiropractor, physical and massage therapists,

4

5

7

11 12

10

13 14

15 16

17

18 19

20 21

22 23

24 25

which Grlicky has paid \$6,756.95 out of pocket, to date. Tilly Dorenkamp

and holistic practitioner—came at a combined cost in excess of \$23,800.08, of

- 48. Tilly Dorenkamp ("Dorenkamp") is an individual who resides in Pinellas Park, Florida. Dorenkamp is an artist with average yearly income from commissions of \$20,000 - \$25,000 per year. She enjoyed excellent muscle tone due to attending Pilates classes roughly five times per week for several years. On the recommendation of a friend, Dorenkamp purchased FasciaBlaster in October 2016 hoping to relieve pain from fibromyalgia and arthritis, and carefully adhered to the instructions provided in Defendants' YouTube videos.
- 49. Dorenkamp then learned about and opted to take part in ASPI's putative clinical trial from December 2016 through March 2017. Per the study protocols, five times per week she used a portable sauna device for 20 minutes, then 'blasted' for five minutes per target area: her abdomen, and then the front, back, inside, and outside of each leg (i.e. 20 minutes per leg in total). A month into the study she was given a FaceBlaster, and began 'blasting' her face and neck to reduce the effects of aging. As the putative clinical trial progressed, Dorenkamp complained numerous times that 'blasting': caused severe nerve pain in her legs and knees; worsened the Restless Leg Syndrome ("RLS") from which she suffered at night; and left her utterly exhausted and bedridden such that she could not perform any other physical activity on 'blasting' days. In the last few weeks of the putative clinical trial, Dorenkamp's suffering was so severe that her Rheumatologist suggested she drop out.
- 50. During the putative clinical trial, an anxiety condition which Dorenkamp had previously managed for 20 years—with anti-anxiety medication Clonazepam (.5 mg)—suddenly worsened, and developed into deep depression, causing her primary care physician to double her Clonazepam dosage and prescribe

an extra half-dose of an additional anti-anxiety medication, Zoloft. Dorenkamp failed to draw a connection between her depression and the putative clinical trial until May of 2017. To date, her exacerbated anxiety condition gives her stress headaches almost every time she leaves the house, which was not the case before her FasciaBlaster experience. She was prescribed yet another anti-anxiety medication, Buspirone (15mg), in early September of 2017.

- 51. After the putative clinical trial ended, Dorenkamp tried 'blasting' three more times. The third time, on May 9, 2017, abruptly brought on a severe thunderclap headache, and elevated her resting heart rate to 185 beats per minute ("BPM") (from her average resting heart rate of approximately 67 BPM), necessitating an emergency room visit. Before this ER visit, Dorenkamp had managed a Tachycardia condition for 20 years with 50mg prescription of Atenolol. Following this ER visit, her cardiologist doubled her Atenolol dosage due to severely worsened heart palpitations, elevated pulse, and mitral valve prolapse diagnoses. The cardiologist also prescribed a nuclear stress test which Dorenkamp has yet to undergo because the entire \$1,000 cost will have to come out of pocket.
- 52. Beyond her cardiological difficulties, 'blasting' severely increased what had previously been quite minimal cellulite on Dorenkamp's legs; the skin now sags off of her lags, there is a conspicuous dent in her thigh, and her calf muscle atrophied to the point that she cannot see it and can barely feel it. 'Blasting' her face and neck has also caused severely sagging skin, dramatically accelerating the appearance of aging, notwithstanding that she was assiduously faithful to ASPI researchers' and YouTube video instructions at all times.
- 53. Before she began 'blasting,' on an average day Dorenkamp experienced a pain level of 3-4 (out of 10) from her fibromyalgia and arthritis conditions. Since May of 2017, on an average day her pain level is 5-7 out of 10, notwithstanding her efforts to manage the pain with ibuprofen and powerful

 painkiller Tramadol (200mg). Her RLS condition has also worsened considerably, disrupting her sleep cycles more than it ever had before. Dorenkamp has not been able to work on her art since December 2016, and as a result she has multiple commissions outstanding, harming her professional reputation.

- 54. Dorenkamp has been subject to defamation, harassment, intimidation, and cyber-bullying, constituting intentional infliction of emotional distress by Defendants, and others on their behalf, in retaliation for her having honestly relayed her experiences in e.g. the "Ashley Black Guru" group discussion page on Facebook. Dorenkamp was also the victim of malicious prosecution in the form of a frivolous lawsuit against her by Defendants, which has been dismissed. Recently, at Defendants' behest and direction on information and belief, individuals⁹ supporting Defendants have sought to harass, embarrass, and intimidate Dorenkamp on Facebook by the unauthorized public posting of unflattering photos of her, and health-related records which, on information and belief, Defendants permitted to be publicized in violation of numerous statutes and regulations, e.g. HIPAA.
- 55. On information and belief, Dorenkamp's FasciaBlaster use will have necessitated medical and therapeutic treatments costing her more than \$15,000.

G. Dina Salas

56. Dina Salas ("Salas") is an individual residing in Las Vegas, Nevada. Salas is 40 years old, has Multiple Sclerosis ("MS"), and in spite of a vegan diet and taking yoga classes three times per week, she was frustrated and embarrassed by cellulite on her thighs, knees and calves. In June of 2016, her cousin told her about FasciaBlaster. Salas purchased one, but did not begin using it until October or

⁹ The individuals in question undertook the described cyber-bullying for Defendants' benefit *if*, that is, they are not in fact merely fake Facebook personae operated by Defendants themselves, as alleged herein. See e.g. Para. 94, *infra*.

4

12 13

11

15

14

17

18

19 20

23 24

25

26 27

28

November of 2016, and only approximately twice a week, and gently, because it was so painful. Salas saw no beneficial results, only dramatic bruising, and stopped 'blasting' in or around December 2016.

- Notwithstanding that she had already stopped 'blasting,' Salas remained a member of the Defendants' "FasciaBlasters" Facebook group, and in early 2017 on the basis of new success stories and compelling 'before and after' photos still cropping up in her Facebook News Feed, she decided to give 'blasting' another try. This time her regimen entailed 'blasting' roughly every other day, and much more strenuously, as she was encouraged by Defendants and others 10 in the discussion group to do so at a pain level of 7 out of 10. Salas saw no positive results, only renewed, dark bruising.
- 58. A few weeks after reinitiating her 'blasting,' as Salas's enthusiasm began to wane yet again, in her Facebook News Feed she saw a video posted by Defendant Black with a caption¹¹ asserting that FasciaBlaster is effective at treating Parkinson's disease and MS—both neurodegenerative conditions—by "lessen[ing] lesions," i.e. the scars on the brain and spinal cord which cause MS. Further research on Google then led Salas to a posting by Defendant(s) on social media

¹⁰ Notably, shortly after Salas had renewed her attention to the Facebook group, she received multiple Facebook friend requests from previously unknown individuals, who were then enthusiastic FasciaBlaster cheerleaders, pushing and prodding Salas to keep up the aggressive 'blasting' every time she expressed any doubts. On information and belief, these individuals were either fake Facebook profiles operated by Defendants, or paid motivators operating at Defendants' behest; at one point in or around May 2017, Salas pointedly asked one of them if she were a paid "motivator," and the other profile immediately 'unfriended' Salas.

¹¹ Salas saw this video and its caption before she was summarily kicked out of Defendants' "FasciaBlasters" Facebook group in June of 2017. On information and belief, this claim pertaining to MS may have been removed since then, however not before Salas and others similarly situated relied on it.

abdomen and back to her 'blasting' routine.

59. Approximately a month into her renewed 'blasting' routine, Salas began suffering an extraordinarily severe itchiness. It was so uniquely awful that it sent her to the emergency room and subsequently to a neurologist, who diagnosed her condition as chronic Pruritis. Far from a garden-variety scratchable itch, Salas experienced deep, torturously unyielding irritation everywhere throughout her body, literally from her toes to scalp, and particularly bad in her tongue and eyeballs. The maddening nerve pain deprived Salas of sleep and otherwise disrupted every aspect of her life.

FasciaBlaster, Salas's enthusiasm understandably skyrocketed, and she added her

60. At the beginning of May, tortured by Pruritis, Salas quit 'blasting' for good. Months of 'blasting' did not cure Salas's MS, nor improve it to even the slightest degree as Defendants claimed it would. All of that 'blasting' did, however, significantly worsen her cellulite, and decorated her legs with a brand new network of unsightly spider veins, where she had previously had none. For the first time in decades, Salas experienced severe and painful oral Herpes outbreaks *repeatedly* since first using the FasciaBlaster. She also gained 20 pounds since first 'blasting,' attributable thereto on information and belief because she had made no other change

¹² On information and belief, some if not all of these individuals whom Salas saw extolling the virtues of 'blasting' for MS treatment were/are fake Facebook profiles or paid motivators. See e.g. Para. 94, *infra*.

to her vegan, yoga-enthusiast lifestyle.

- 61. Along with the total failure to improve her MS in the slightest, her abrupt weight gain, brand new spider veins, resurgent Herpes outbreaks, and torturous unscratchable itching from head to toe, on information and belief Salas's 'blasting' disrupted her hormonal levels, all of which combined to throw her into severe depression.
- 62. To date, the various medical treatments necessitated by Salas's FasciaBlaster experiences add up to approximately \$4,000 out of her pocket and several thousand more paid on her behalf in financial assistance, on information and belief. This figure of course fails to account for e.g. the future cosmetic treatments required to fully repair all the damage wrought by Defendants' products and business practices.

H. Arlene Rodriguez

- 63. Arlene Rodriguez ("Rodriguez") is an individual residing in Hanford, California. She is a 38 year-old waitress. After seeing Defendants' advertising in her Facebook News Feed, she joined the Facebook "FasciaBlasters" discussion group to research the product. Seeing no meaningfully negative reviews, and eager to get rid of cellulite on her thighs, she purchased the device in mid-November 2016 and in late November commenced 'blasting' her thighs, abdomen, and arms, for roughly five minutes in total, roughly three times per week in a very hot bath or shower.
- 64. Right away, Rodriguez would experience nausea, dizziness and lightheadedness almost every time after 'blasting,' and frequently headaches. Beginning in mid-December, Rodriguez began experiencing burning body aches as well, which were sufficiently worrisome that she went to a doctor to be tested for Lupus, arthritis, etc., but the tests were negative. She combed the Facebook discussion group for feedback similar to her experiences from other users, and finding none, Rodriguez carried on 'blasting.' Even as the cellulite which motivated

her purchase was worsening substantially, Rodriguez continued 'blasting' in reliance on Defendant Black's representations that increased appearance of cellulite is a temporary result of FasciaBlaster's breaking up the fascia in "layers," and Defendants' famous, persistent refrain: "worse before better!"

- 65. In mid- December, Rodriguez began experiencing unusual mood swings and increased anxiety, but failed to draw any connection to her 'blasting.' In or around February 2017 Rodriguez bought a second FasciaBlaster, the 'Mini 2' model, and extended her 'blasting' sessions to an average of seven minutes on the basis of enthusiastic encouragement and authoritative advice and promises made by Defendants (and other Facebook profiles which, on information and belief, were either fake, or paid motivators) in Defendants' Facebook discussion group. In or around March 2017, seeing her doctor about her unexplained persistent mood swings and increased anxiety, she was prescribed Zoloft (15mg).
- 66. In or around May of 2017, Rodriguez's body aches grew so severe that at one point she was bedridden for two days, yet she persisted in 'blasting.' Not long thereafter, she happened upon a report about FasciaBlaster on the Facebook page of Goop, a trendy lifestyle company. Among the public's comments on the Goop posting was a link to a Facebook group for dissatisfied FasciaBlaster users, providing Rodriguez's first inkling that the device might be remotely fallible; the user comments in this second Facebook group constituted the first meaningfully negative reviews about FasciaBlaster which Rodriguez had seen, after roughly six months of participating in Defendants' own carefully monitored, controlled, 100% enthusiastically positive discussion group. Rodriguez promptly stopped blasting at this point, and began to make more pointed and less positive inquiries in the Defendants' Facebook discussion group. She was then promptly kicked out of that group, and blocked from the "Ashley Black Guru" Facebook page wherein she might otherwise have been able to comment about her experiences e.g. for the

benefit of third parties.

- 67. Between a week and 10 days after Rodriguez ceased 'blasting,' she developed the beginnings of a strange rash on her lower back. After another week it had begun to spread, and it itched severely. Her doctor initially diagnosed the rash as an allergic reaction, and prescribed Loratidine (10mg). Another week or two later, the rash had spread like wildfire, all over Rodriguez's thighs, back, sides, breasts, upper chest, and down her right arm. She returned to the doctor, who inquired whether Rodriguez had traveled recently, or eaten anything exotic, or undertaken any other new experience or meaningful lifestyle change of any kind. The answer was no, and Rodriguez mentioned FasciaBlaster. Her doctor had never heard of it, so Rodriguez explained Defendants' 'blasting' theories, to which the doctor expressly replied that there was "a strong possibility" that FasciaBlaster had caused the rash, and prescribed a 10-day course of steroid Prednazone (5mg).
- 68. Rodriguez took her prescribed Prednazone for 10 days, during which the rash improved. Three days after the tenth day, however, the rash returned aggressively, even worse and more painful than it had been previously, and extremely unsightly (the factfinder will undoubtedly find photos thereof to be highly upsetting). Rodriguez went back to the doctor again, had tissue samples taken for biopsy, and was given a prescription for anti-fungal medication Terbinafine (250mg) which she only took for a short time before receiving her biopsy results back with her diagnosis: chronic superficial perivascular dermatitis, i.e. inflammation of her blood vessels. In response, her doctor doubled the previous Prednazone prescription dosage (to 10mg) and tripled its duration (30 days), added prescriptions for Ranitidine (150mg) and Triamcinolone (1%) steroid cream to the menu, and advised Rodriguez to supplement all of the foregoing with Benadryl any time the itch grew too unbearable. All of the foregoing finally began to put the rash on the retreat, and at the end of 30 days, the doctor prescribed another 30 days of

half the previous Prednazone dosage (back down to 5mg), then another 30 days of the next lowest available dosage (1mg) in order to wean Rodriguez off of it; the rash is much improved as of the date hereof but, notably, it is not gone.

- Ouring the Summer of 2017, temperatures in California's Central Valley routinely exceeded 100 degrees. At that time, at the height of Rodriguez's extremely unsightly rash, she was obliged to wear long sleeved shirts and long pants to cover it, rather than the tank tops and shorts or skirts most women would prefer to wear on hundred-degree days. Obviously such clothes were highly uncomfortable, and the predictably profuse sweating that resulted ramped up Rodriguez's already itchy discomfort into a painful burning sensation. On two occasions, between June and July, she was sent home early from her waitressing job because constantly-scratching waitresses are not good for business. She lost wages and tips totaling \$300 or more as a result.
- 70. As of the date hereof, almost 11 months since she first 'blasted,' Rodriguez's cellulite remains worse than it was before, and has spread from her thighs to her buttocks, where it had not appeared previously. Her inner thighs bear distinct, unsightly rake-marks (matching the dimensions of the FasciaBlaster claws), notwithstanding that roughly five months have passed since she last raked them. Rodriguez had minor spider veins on her outer knees before she purchased FasciaBlaster. As of the date hereof, those spider veins are significantly darker, thicker, wider, and more unsightly than they were, and they have been joined by brand new networks of unsightly spider veins above her knees, prominently on the front of her thighs.

I. Jerry Gaines

71. Jerry Gaines ("Gaines") is an individual residing in Tampa, Florida. He is the grandfather of Plaintiff Lanum. When the latter purchased multiple FasciaBlaster devices in November of 2016 (see Para. 28, supra), she gave one to

, 26

Gaines and told him to only use the device on his head and neck—pursuant to the "migraine relief protocol" specified by Defendants' on their FasciaBlaster Facebook page, and to emulate Defendants' online videos, photos and testimonials of subjects from a putative hair growth study—and on his abdomen as recommended by Defendant Black in other marketing and instructional materials. Gaines 'blasted' two to three times per week, for twenty minutes at a time in the shower or sauna, beginning in late November 2016, right up until he suffered a stroke in June 2017. Gaines suffered damage to cranial nerve no. 7, adversely affecting his speech and causing severe expressive aphasia. CT scan results revealed "loss of grey-white differentiation and cortical effacement in the left frontal cortex, in the left MCA [(middle cerebral artery)] distribution." Another scan revealed "left M2 [a segment of the MCA] with diminished flow." A third test, cerebral angiography, showed "distal M2 occlusion." A fourth test, brain MRI, showed "acute left MCA territory infarct in the left frontal lobe + a few areas of punctate restricted to fusion in the right frontal and parietal lobes."

72. Following Gaines's stroke, Lanum found testimonials from dissatisfied FasciaBlaster users online, which made reference to the device's dangerous tendency to release blood clots. Lanum brought the foregoing to the attention of Gaines and his physician, and the latter demanded that Gaines immediately cease all 'blasting'; specifically, his doctor expressly said "throw that thing [FasciaBlaster] away!" Since then, Gaines has had to undergo extensive speech therapy and cognitive exercise programs, as well as physical therapy and treatments to restore his neurological system, including multiple weeks at an expensive in-patient rehabilitation facility.

Class Action Allegations

73. Plaintiffs bring this action on their own behalf and as a Class Action under the provisions of e.g. Cal. Civ. Code § 1781, on behalf of all members of a

plaintiff Class defined as: all persons who have purchased and/or used FasciaBlaster, or who will have done so at some point prior to resolution of the Plaintiffs' claims herein.

- 74. Plaintiffs do not know the exact number of claimed Class members, but on information and belief, they number in the tens of thousands if not more. Due to the nature of the trade and commerce involved, the claimed Class members are sufficiently numerous and geographically dispersed throughout the U.S. so that the joinder of all claimed Class members is impracticable.
- 75. There is considerable commonality here among the claimed Class members in that each has purchased or used, or will have purchased or used, a dangerous FasciaBlaster device(s) prior to e.g. the implementation of any injunctive relief ordered as a result of this lawsuit. The various harms FasciaBlaster has wrought on each Plaintiff constitute further commonality between each Plaintiff and all claimed Class members who have suffered, or will suffer before this matter is resolved, the same or substantially similar¹³ type(s) of physical and commercial injuries as any given Plaintiff(s); hopefully, many claimed Class members have been fortunate enough to avoid serious injury, but any individual who nevertheless has failed or will fail to achieve the 'blasting' results promised by Defendants finds commonality with the Plaintiffs regarding e.g. causes of action for false advertising, breaches of express and implied warranty, and fraud, if not also others.

¹³ For example, Plaintiff Elson alleges that the Epstein-Barr virus which previously lay harmlessly dormant in her system was released and reawakened by 'blasting,' making Elson extremely ill. (See Para. 13, supra.) There is thus commonality between Elson and any putative Class member who also became ill after having a previously dormant virus reactivated by FasciaBlaster use; the possibility that the Class member's specific virus might differ (e.g. Shingles) does not inherently defeat the commonality of the cause, nor the consequences, of its revival from prior dormancy.

- 76. Plaintiffs and claimed Class members have a common interest in determining the following:
 - (a) whether Defendants engaged in false or misleading advertising;
 - (b) whether FasciaBlaster caused the injuries suffered by users thereof;
 - (c) whether acts and omissions by Defendants contributed to the injuries suffered by FasciaBlaster users;
 - (d) whether acts and omissions by Defendants were negligent, grossly negligent, reckless, fraudulent, or any combination thereof; and
 - (e) that Plaintiffs and other members of the claimed Classes have been, or are substantially likely to be, damaged by Defendants' wrongful acts and/or omissions.
- 77. Plaintiffs' claims are typical of the claims of all Class members. Plaintiffs will fairly and adequately protect the interests of the Classes. Plaintiffs are typical users of FasciaBlaster devices and accessories sold throughout the United States. Their interests are coincident with, and not antagonistic to, those of the other members of the Class. In addition, Plaintiffs are represented by counsel who are competent and experienced in the prosecution of class action litigation.
- 78. The prosecution of separate actions by individual members of the plaintiff Class would create a risk of inconsistent or varying adjudications, potentially establishing incompatible standards of conduct for Defendants and inconsistent remedies available to injured Class members nationwide.
- 79. The questions of law and fact common to the members of the Subclasses predominate over any questions affecting only individual members, including legal and factual issues relating to liability for actual, general, and punitive damages, and appropriateness of injunctive relief.
 - 80. A class action is superior to other methods for the fair and efficient

adjudication of this controversy. Treatment as a class action will permit large numbers of similarly situated persons to adjudicate their common claims in a single forum simultaneously, efficiently, and without the duplication of effort and expense that numerous individual actions would engender. Class treatment will also permit the adjudication of claims by many Class members who could not afford individually to litigate the numerous claims such as are asserted in this Complaint. The plaintiff Class is readily ascertainable. Finally, this class action is not likely to present such difficulties in management that would preclude its maintenance as a class action.

IV. FACTS COMMON TO ALL CAUSES OF ACTION

FasciaBlaster Marketing

- 81. Defendants do or did advertise FasciaBlaster through multiple media avenues, including *inter alia*: website www.fasciablaster.com; website www.AshleyBlackGuru.com; Defendant Black's book <u>The Cellulite Myth: It's Not Fat, It's Fascia</u>; pervasive targeted advertising, putatively instructional videos, and putatively open discussion forums on social media websites/applications including *inter alia* Facebook, Instagram, and YouTube; and by promotional interviews and other varieties of marketing tie-ins e.g. on the Today Show and EXTRA television programs, in Essence and Shape magazines, and on the much-ballyhooed lifestyle website GOOP.com.
- 82. Putatively instructional materials (e.g. over 100 videos) and discussion-oriented forums (e.g. multiple Facebook discussion groups) created and/or

¹⁴ On information and belief, Defendants enjoy Facebook's top-of-the-line targeted advertising package, whereby Facebook's algorithm communicates with a user's web browser program to learn that e.g. she had previously run a Google search for "cellulite," causing Facebook to automatically place Defendants' ad prominently near the top of the user's Facebook 'News Feed' the next time she scrolls through it.

9

12

13 14

15 16

17

18 19

20

21 22

24

23

25 26 27

28

1 moderated by Defendants feature public representations asserting or purporting to reinforce assertions about the effectiveness of Defendants' products and techniques for their advertised purposes. Moreover, on information and belief Defendants did and do create and operate shill (i.e. fake) Facebook profiles, and/or surreptitiously contract with third party 'motivators,' in order to give the false public impression that these are disinterested parties as they broadcast glowing third-party feedback and/or oppose, attack, and seek to undermine any negative third-party feedback. Finally, representations on product packaging also qualify as marketing.

- All putatively 'informational' material disseminated by Defendants regarding FasciaBlaster, in any medium, has the underlying intent and effect of advertising FasciaBlaster products, accessories and techniques. On information and belief, most if not all of the foregoing relies on false and/or deceptive claims pertaining to health benefits, aesthetic benefits, and the putatively scientific bases for such claims, including but not limited to false representations of the medical/academic qualifications of individuals and regulatory agency support for the outcomes promised by the Defendants.
- The following is a nonexhaustive list of Defendants' false and/or 84. misleading representations about FasciaBlaster's health benefits, aesthetic benefits, the medical/academic qualifications of Defendants' agents and employees, the scientific legitimacy of Defendants' putative clinical trial, and regulatory agency support for Defendants' commercial promises, inter alia:
 - Defendants have stated that FasciaBlaster is "FDA Approved." oIn fact, FasciaBlaster is merely registered with the FDA, as a Class 1 medical device ("massager"). Class 1 devices are considered low-risk and subject to the lowest degree of regulatory control. For example, dental floss is classified as a Class 1 device. FasciaBlaster is not FDA approved for the myriad medical uses promoted by Defendants.

(b) Defendants claimed as far back as September 2016, if not earlier, that their products were subject to "clinical study" and "double-blind scientific research." •In fact, on information and belief the only putatively scientific research was the putative clinical trial undertaken at ASPI from mid-December 2016 through mid-March 2017.

Moreover, as noted *supra* by participant Plaintiffs, the study was dubiously scientific, was conducted without IRB oversight, violated HIPAA and FDA protocols, and was certainly not "double-blind" because there was no control group versus test group, but rather simply 35 participants all doing the same 'blasting' and submitting their results. Contrary to innumerable prior representations by Defendant Black and others, an officer of Defendant ADBI recently admitted that there has been no genuine "clinical" study.

- (c) <u>Defendants have claimed and/or intentionally implied, inter alia:</u>
 that Defendant Black is a Licensed Massage Therapist, scientist, and
 "Inventor of the Year" nominee; that former spokesperson Dari Samia
 is a medical doctor; that spokesperson and putative researcher Bart

 Jameson is a doctor; and that spokesperson and putative researcher

 Kathleen Stross is a neuroscientist. •In fact, on information and belief,
 none of these people possess the referenced qualifications.
- (d) Defendants have claimed that FasciaBlaster is 100% safe; on May 18, 2017, Defendant Black stated in a promotional video that no woman had reported injuries to her; as recently as August 31, 2017, Black stated "[t]here are no serious injuries reports (sic) ... [w]e investigate all claims." •In fact, on information and belief, thousands of FasciaBlaster users have experienced adverse effects from 'blasting.' According to an FDA Inspection Report, a minimum of 70 such users

28

reported their injuries directly to Defendants, and were systematically ignored. (See Paras. 89-90, infra.) On information and belief, anywhere between dozens and thousands of FasciaBlaster users complained, or merely inquired, about adverse experiences from 'blasting' on e.g. social media forums, before Defendants censored or deleted their comments and questions, and banned them from further participation in said forums to prevent potential customers from seeing honest feedback of a negative nature. Plenty of these complaints were raised before May 18, 2017; on information and belief, Defendant Black has received numerous complaints dating back more than a year before she made this claim. Many reports were provided to Defendants pertaining to users whose injuries were serious enough to require emergency hospitalization, including multiple Plaintiffs herein and others similarly situated, and as explicitly noted in the FDA Inspection Report of which Black had full knowledge before publicly claiming otherwise on August 31, 2017.

- (e) <u>Defendants have claimed that FasciaBlaster use will not affect</u>
 hormones and will not increase estrogen levels. oln fact, the
 experiences of multiple Plaintiffs and others similarly situated
 demonstrate the dramatic effects FasciaBlaster use has wrought on their
 hormone levels, including extreme cramping, missed periods, unusual
 menstrual bleeding (e.g. lasting up to 10 days), depression, anxiety, etc.
- (f) Defendants did and/or do claim that FasciaBlaster reduces the appearance of varicose veins, and is "100% effective" at treating cellulite, purportedly "better, faster, and more affordable than [competing approaches to cellulite reduction] freezing [i.e. CoolSculpting®] or surgery [e.g. liposuction]." •In fact, after 'blasting'

1

2

3

5

multiple Plaintiffs experienced a marked increase in the appearance and severity of cellulite, varicose and spider veins, and these worsened conditions have persisted long after they ceased 'blasting,' six months later or more.

- (g) <u>Defendants did and/or do claim that FasciaBlaster erases lines</u> and wrinkles. •In fact, 'blasting' worsened the lines and wrinkles of multiple Plaintiffs and others similarly situated.
- Defendants have claimed that bruising from FasciaBlaster is (h) "healthy, restorative, and cleansing[,]" and that, at any rate, any such aesthetic side effects of any kind are only temporary and will improve with continued 'blasting' in keeping with Defendant Black's oftrepeated refrain, "worse before better!" •In fact, notwithstanding faithful adherence to Defendants' instructions for use, multiple Plaintiffs and others similarly situated have had the following side effects persist through, and well after, prolonged 'blasting': hemosiderin staining, crêpe skin, loose skin, fallen face, persistent claw lines/rake marks, inflammation, Oxidative stress, crepitus, weight gain, adrenal fatigue, thyroid disruption, hematoma, blood clot, burst blood vessel, hormonal changes, mood swings, depression, anxiety, panic attacks, Vasovagal Syncope, heart palpitations, difficulty breathing, lightheadedness, vertigo, flu-like symptoms, nerve pain, joint pain, muscle pain, muscle spasms, headaches, numbness, chronic Pruritis, itching or burning sensations, rash, chronic perivascular dermatitis, hives, hair loss, viral outbreaks, chest pain, etc.
- (i) <u>Defendants' various websites and social media profiles feature</u> multiple sets of promising 'before and after' photos to demonstrate the results FasciaBlaster provides. Subject to proof: many of the photos

are digitally altered, others appear to have been copied from various plastic surgery or liposuction websites, and on information and belief, including according to former FasciaBlaster spokesperson Dari Samia, at least one pair of pictures was taken mere moments apart, but with different lighting giving them the appearance of improvement from one to the next. On information and belief, at least one pair of photos feature a woman who was eight-months pregnant in the 'before' photo, then four or five months postpartum in the 'after,' which Defendants fail to disclose in presenting them as indicative of successful 'blasting'.

Fasciablaster's Chemical Composition

- 85. Plaintiffs are informed and believe, and thereon allege, that FasciaBlaster has been and is dangerous and defective in its design, and unfit to be used for any purpose by any person, and that Defendants have been on actual and constructive notice of said unfitness at all relevant times.
- 86. On information and belief, the chemical composition of the plastic in a FasciaBlaster device includes more than 40% Bisphenol A ("BPA"), which can both mimic and antagonize estrogen in the body. Multiple scientific studies link BPA to endocrine system disruption, dating as far back as 1997. Studies have linked BPA's xenoestrogenic effects to, *inter alia*, metabolic disease, thyroid disruption, neurological damage, interference with fetal and early childhood development, dopaminergic harms (e.g. attention deficits and increased susceptibility to drug addiction), and multiple cancers (most prominently, breast cancer).
- 87. Studies have also demonstrated—and sources including Mayo Clinic and Harvard University School of Public Health warn—that exposure to heat can cause BPA to leach out of plastic at especially dangerous levels.
- 88. Notwithstanding the foregoing, Defendants did and do direct FasciaBlaster users to use copious heat in their 'blasting' routines; each named

Plaintiff followed such instruction, and 'blasted' only during or immediately after a sauna or very hot bath or shower. For example, Plaintiff Lanum used a portable sauna device which was provided to every participant in the putative "clinical trial" at ASPI; Plaintiff Haavisto's husband built a sauna for her in their home—at substantial expense—specifically for 'blasting' purposes when she bought FasciaBlaster; Plaintiff Gaines would always 'blast' during a hot shower. On information and belief, tens of thousands of FasciaBlaster users follow Defendants' guidance for use under temperature conditions which dramatically increase the risk of BPA leaching from the device into their skin. Moreover, on information and belief, Defendants' recommended oils and moisturizers risk further increasing dermal penetrability, i.e. the ease with which a toxin like BPA can slip into the user's body through her skin.

FDA Inspection

89. Between July 18 and August 4, 2017, an investigator from the U.S. Department of Health and Human Services ("DHHS"), Food and Drug Administration ("FDA") found numerous faults with Defendants' business practices, detailed in Establishment Inspection Report FEI # 3012547534 ("FDA Inspection Report"), which the Plaintiffs submit herewith as "Exhibit A."

Among other things, the FDA Inspection Report reflects the Investigator's determinations that:

- (a) Defendants had failed to develop, maintain, or implement procedures for Medical Device Reporting ("MDR") by consumers.
- (b) Defendants were aware that 70 MDRs had been filed in the preceding year alleging injury by FasciaBlaster, but Defendants had nevertheless failed in every instance to initiate any corrective and preventive procedures ("CAPA") to address them.
- (c) Defendants had in fact "failed to define[], document[], or

implement[] [any] CAPA procedure to analyze, for example, processes, work operations, recurring complaints, returned product and other sources of quality data that identify existing and potential causes of nonconforming product or other quality problems."

- (d) Defendants have "been importing their FDA registered, Class I medical device for at least 18 months, beginning initially ... in 2015 but there was no evidence that complaints older than 01 month have been evaluated."
- (e) The foregoing might be explained in part by the fact that, for every example of a user complaint which the Investigator cites in her report, she notes either that "I found minimal..." or "I found no evidence that an attempt was made to determine the relationship, if any, of the device to the reported incident or adverse event to evaluate if it was MDR reportable[,]" or that "I found no evidence that an attempt was made, after learning the batch number of the medical device, to determine why the medical device malfunctioned or if it was due to a failure to meet design specifications." (Emphasis added.)
- (f) "Multiple complaints began to come into FDA's MDR database" as far back as "June 2016" and, the Investigator explicitly makes note, multiple consumers reported requiring hospitalization for their injuries.
- (g) "The FasciaBlaster and AshleyBlackGuru (websites) appear to make structure/function claims that exceed the limitations of a Class II (*sic*) medical device."
- (h) "The website makes disease claims by asserting that the medical device can alleviate the symptoms of specific diseases. For example,

Restores Blood flow (cardiovascular disease)
Increases Nerve Activity (rheumatoid arthritis)